Pharmaceuticals

After a successful shift to a royalty model, the firm reports stronger financials and confirms it is weighing a merger or acquisition.

Sangamo pushes a promising Fabry disease therapy toward the FDA while a cash crunch forces a strategic pivot to brain-targeting neurological cures.

NASDAQ-listed Bio Green Med Solution abandons its biopharma roots for fire safety, slashing losses but facing new questions about its long-term survival.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

The new DSP leverages 100% first-party HCP data, script-lift measurement, and sustainability metrics to offer unparalleled precision and performance.

Formerly Asha Therapeutics, the biotech rebrands with top talent and an AI platform that designs novel medicines from scratch for humanity's toughest diseases.

Danish firm Evaxion, backed by the Gates Foundation, uses its AI platform to design a next-gen polio vaccine, aiming to end the disease for good.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

Tenpoint Therapeutics launches YUVEZZI, a once-daily drop for presbyopia, entering a fierce market with a novel two-in-one formula for aging eyes.

German CDMO Vetter wins a prestigious, client-voted award, underscoring its pivotal role and massive €2 billion investment in the world of injectable biologics.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new partnership aims to merge digital brain therapies with functional foods, targeting Japan and Southeast Asia's rapidly growing elderly populations.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.

LIB Therapeutics' new monthly, room-temperature stable cholesterol drug shows strong long-term data, challenging rivals with a focus on patient ease-of-use.

Japanese pharma giant Meiji Seika Pharma backs Centivax's quest for a universal flu vaccine, a move that could revolutionize global pandemic preparedness.

A Georgia firm's painless patch technology earns top honors, promising to revolutionize medicine delivery and solve critical global health challenges.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.